Combioxin raises CHF 1.1 M

Combioxin is developing a drug for acquired immune deficiency in intensive care patients. Together with the University of Bern, it has secured CHF 1.1 million in non-dilutive support from Innosuisse for this project.

Announced on
Round
Grant
Amount
CHF 1.1 M
Location
Epalinges, canton of Vaud
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic